Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SANGUINE CORP. (SGNC) -- Ignore unavailable to you. Want to Upgrade?

To: Gwolf who wrote (51)	6/5/1998 1:22:00 PM
From: Gwolf	Respond to of 5402

A Wall Street Journal article dated June 3,1998 talks about Baxter dropping their own bid to create a synthetic blood. The article also talks about their purchase of $190 million dollars worth of Somatogen stock. They have a blood substitute that is years away from being marketed. The point is that the major drug companies do invest millions in companies that they think have an exciting new product. I personally think this is what is going to happen to SGNC long before they get to market with a product. Gwolf